Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

140 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) improves prognosis in locally advanced breast cancer patients: an update of the Southern Italy Cooperative Oncology Group (SICOG) randomised trial 9908.
Frasci G, D'Aiuto G, Comella P, D'Aiuto M, Di Bonito M, Ruffolo P, Iodice G, Petrillo A, Lastoria S, Oliviero P, Capasso I, Montella M, Siani C, Santangelo M, Vizioli L, Comella G; Southern Italy Cooperative Oncology Group (SICOG) Italy. Frasci G, et al. Among authors: comella p, comella g. Ann Oncol. 2010 Apr;21(4):707-716. doi: 10.1093/annonc/mdp356. Epub 2009 Oct 8. Ann Oncol. 2010. PMID: 19815652 Free article. Clinical Trial.
Weekly dose-dense cisplatin-epirubicin-paclitaxel administration with granulocyte colony-stimulating factor support does not substantially improve prognosis in extensive disease small-cell lung cancer. A SICOG phase II study.
Frasci G, Comella P, Carreca I, DeCataldis G, Muci D, Brunetti C, Russo A, Palmeri S, D'Aniello R, Giordano R, D'Aiuto M, Comella G; Southern Italy Cooperative Oncology Group. Frasci G, et al. Among authors: comella p, comella g. Oncology. 2005;68(2-3):223-9. doi: 10.1159/000086778. Epub 2005 Jul 7. Oncology. 2005. PMID: 16015038 Clinical Trial.
Biweekly docetaxel-irinotecan treatment with filgrastim support is highly active in antracycline-Paclitaxel-refractory breast cancer patients.
Frasci G, D'Aiuto G, Thomas R, Comella P, Di Bonito M, Lapenta L, D'Aiuto M, Botti G, Vallone P, De Rosa V, D'Aniello R, Giordano R, Comella G. Frasci G, et al. Among authors: comella p, comella g. Oncology. 2005;68(4-6):391-7. doi: 10.1159/000086980. Epub 2005 Jul 12. Oncology. 2005. PMID: 16020968 Clinical Trial.
Cisplatin-topotecan-paclitaxel weekly administration with G-CSF support for ovarian and small-cell lung cancer patients: a dose-finding study.
Frasci G, Panza N, Comella P, Cartení G, Guida T, Nicolella GP, Natale M, Lombardi R, Apicella A, Pacilio C, Gravina A, Lapenta L, Comella G. Frasci G, et al. Among authors: comella p, comella g. Ann Oncol. 1999 Mar;10(3):355-8. doi: 10.1023/a:1008301222560. Ann Oncol. 1999. PMID: 10355583 Free article. Clinical Trial.
Concurrent irinotecan and 5-fluorouracil plus levo-folinic acid given every other week in the first-line management of advanced colorectal carcinoma: a phase I study of the Southern Italy Cooperative Oncology Group.
Comella P, Casaretti R, De Vita F, Avallone A, Orditura M, Petrillo A, Gravina A, Faranda A, Comis S, Comella G, Catalano G. Comella P, et al. Among authors: comella g. Ann Oncol. 1999 Aug;10(8):915-21. doi: 10.1023/a:1008339010655. Ann Oncol. 1999. PMID: 10509152 Free article. Clinical Trial.
Cisplatin-epirubicin-paclitaxel weekly administration in advanced breast cancer: a phase I study of the Southern Italy Cooperative Oncology Group.
Frasci G, D'Aiuto G, Comella P, Apicella A, Thomas R, Capasso I, Di Bonito M, Cartenì G, Biglietto M, De Lucia L, Maiorino L, Piccolo S, Bianchi U, D'Aniello R, Lapenta L, Comella G. Frasci G, et al. Among authors: comella p, comella g. Breast Cancer Res Treat. 1999 Aug;56(3):239-52. doi: 10.1023/a:1006263226099. Breast Cancer Res Treat. 1999. PMID: 10573115 Clinical Trial.
140 results